Eligibility for Cervical Cancer Treatment in Cuba

Understanding Eligibility

Cervical cancer treatment eligibility in Cuba is determined through a comprehensive medical review of each patient's diagnosis, FIGO staging, prior treatments, and overall health. Cuba's oncology team evaluates each case individually to design the most appropriate treatment plan.

Medical Review Process

The medical review requires:

• Pathology reports — Biopsy confirming cervical cancer with histological type (squamous cell carcinoma, adenocarcinoma, adenosquamous). Colposcopy and cone biopsy reports if performed. • Staging — FIGO (International Federation of Gynecology and Obstetrics) staging, based on clinical examination, imaging, and pathology. • Imaging studies — MRI pelvis (for local tumor extent and parametrial involvement), CT chest/abdomen/pelvis (for distant metastases), PET-CT if available. • Surgical reports — If surgery (cone biopsy, hysterectomy) has been performed, with operative and pathology reports. • Treatment history — Prior radiation therapy details (if any), chemotherapy regimens, and response. • Blood work — Recent complete blood count, liver/kidney function, SCC antigen (squamous cell carcinoma marker) if available. • HPV testing — HPV type (16, 18, other high-risk types) if available. • General health assessment — Medical history including comorbidities, current medications, and overall physical status.

The gynecologic oncology and radiation oncology team reviews these documents to confirm staging and design an individualized treatment plan.

Who Benefits Most

Cervical cancer treatment in Cuba may be particularly valuable for:

• Patients seeking chemoradiation — Cuba has experienced radiation oncology teams and modern brachytherapy capabilities for locally advanced cervical cancer. • Patients seeking a second opinion — Independent review of diagnosis, staging, and treatment plan. • Patients seeking conventional treatment at competitive costs. • Patients interested in experimental immunotherapy — Those with EGFR-expressing tumors who may be eligible for CIMAher clinical trials. • Patients from countries with limited oncology/gynecologic oncology infrastructure. • Patients with recurrent disease — Seeking additional treatment options.

The medical team provides an honest assessment of treatment options for each individual case.

Preparing Your Medical Records

To begin the eligibility review:

• Biopsy/pathology reports (histological type, grade) • Colposcopy and cone biopsy reports (if performed) • FIGO staging documentation • Imaging on CD/DVD (MRI pelvis, CT, PET-CT) • Surgical reports (if surgery performed) • Prior treatment records (radiation therapy plans, chemotherapy regimens) • Recent blood work • HPV testing results (if available) • Current medication list

Documents should ideally be in Spanish or English. SMC Salud assists with translation. The review takes 5-10 business days, after which a treatment proposal with eligibility confirmation and transparent cost estimate is provided.